Please login to the form below

Not currently logged in
Email:
Password:

Pfizer UK appoints Erik Nordkamp as new managing director

He takes over from Jonathan Emms who moves to a global role within the firm
Erik_Nordkamp_WEB

Erik Nordkamp has been appointed as the new managing director and head of the global innovative pharmaceutical business for Pfizer UK.

Nordkamp will take over from Jonathan Emms, who becomes global marketing lead for Pfizer's global established pharmaceutical (GEP) business.

This is a major step up for Emms as GEP has just been significantly boosted by Pfizer's recent $17bn acquisition of injectable medicine specialist Hospira.

Emms led Pfizer's UK business for three years, and in the past year has also served as ABPI president - a role he will be stepping down from in April in order to focus on his new position.

Emms has been at the forefront of the drug pricing debate in the UK as he was both Pfizer UK's general manager and the ABPI president during the negotiations and launch of the new PPRS scheme in January 2014.

Emms said: “I have thoroughly enjoyed leading the Pfizer UK business and it's been a great privilege to serve as ABPI president this past year.

“I'm proud of what has been achieved in both roles and I'd like to see dialogue continue with government in order to improve access and uptake of innovative medicines for UK patients, and achieve the government's aspiration of making the UK a leader in life sciences.”

New leader at Pfizer UK

Nordkamp joined Pfizer in 2010 and for the past year has led Pfizer Greece, Cyprus and Malta, as well as the global innovative pharmaceutical business.

Prior to this, he worked for Pfizer in the UK as head of strategy for primary care, Europe and Canada.

Nordkamp has also served as president of the PhRMA Innovation trade association and prior to joining Pfizer in 2010 he worked for Lilly in Germany and Australia.

Commenting on his appointment, Nordkamp said: “I am delighted to be returning to the UK, a key global hub for scientific innovation. However, with a National Health Service under strain, the UK is in a situation where patients are not always able to gain access to the most innovative medicines.

“Industry can play a vital role in finding solutions to these challenges, and I look forward to continuing conversations with government, the NHS and NICE to ensure the value of our industry is recognised, and health is seen as a longer term investment rather than a short-term cost. Patients have a right to get the right medicines at the right time.”

Article by
Ben Adams

10th February 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics